Home / Tag Archives: DynPort Vaccine Company

Tag Archives: DynPort Vaccine Company

CSRA’s DynPort Vaccine Company Gets Orphan Drug Designation on Plague Vaccine

TYSONS CORNER, VA, March 10, 2017 — A subsidiary of CSRA (NYSE: CSRA) has secured orphan drug status from the Food and Drug Administration on a plague vaccine it is developing as a potential pre-exposure prophlaxis treatment against Yersinia pestis infection, ExecutiveBiz reported Thursday. The company said Wednesday the designation enables DynPort Vaccine Company to …

Read More »

Gary Nabors: CSC Arm to Assess New Compounds for NIH’s Anti-Infectives Program

A Computer Sciences Corp. (NYSE: CSC) company has won a 10-year, $90 million follow-on contract to examine infectious disease therapeutics for the National Institutes of Health’s anti-infectives program. DynPort Vaccine Company LLC will conduct first phase clinical trials of new compounds to support the National Institute of Allergy and Infectious …

Read More »